Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QVA149 versus triple therapy in moderate to severe COPD without frequent exacerbations
NL-OMON43821Phase 4Active, not recruiting
- Sponsor
- TFS HealthScience
- Start
- Apr 2016
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of indacaterol + glycopyrronium, tiotropium and salmeterol + fluticasone in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by TFS HealthScience. Primary endpoint: Primary objective. Started Apr 2016; status: active, not recruiting.
02
Drugs
indacaterol + glycopyrroniumtiotropiumsalmeterol + fluticasone
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NL-OMON43821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43821.